Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
Therapeutic Antibody Development Services
Solutions
Online Inquiry

Therapeutic Antibody Development Services

Antibody therapies are a large and rapidly expanding class of drugs that can provide significant health benefits. Alfa Cytology offers therapeutic antibody development services, to provide clients with different forms of therapeutic antibodies for cancer therapy.

Therapeutic Antibody for Cancer Therapy

More than 100 antibody-based therapies are now approved for a wide range of serious human diseases, with cancer being one of the most successful cases of antibody therapies. Most of the approved antibodies are in IgG form, and a number of alternatives are emerging, including antibody-drug couplings (ADCs), domain antibodies, bispecific antibodies (BsAbs), IgG mixtures, and antibody fusion proteins.

Targets of Therapeutic Antibodies Examples
B-cell Lineage Markers
  • CD19
  • CD20
Growth Factor Receptors
  • Epidermal growth factor receptor (EGFR)
  • Human epidermal growth factor receptor 2 (HER2)
Immune Checkpoint Inhibitors
  • Programmed cell death protein 1 (PD-1)
  • Programmed death ligand 1 (PD-L1)
Angiogenic Growth Factors
  • Vascular endothelial growth factor (VEGF)

Antibody-based therapeutics for oncology.Fig.1 Antibody-based therapeutics for oncology. (Carter, P. J., & Rajpal, A., 2022)

Our Services

The success of antibodies in oncology therapeutics has inspired significant efforts to develop next-generation anticancer antibodies that can improve response rates or extend the duration of responses. Alfa Cytology offers a diverse range of therapeutic antibody development services to provide customers with different forms of anticancer antibodies.

Therapeutic Monoclonal Antibody

Therapeutic Monoclonal Antibody

Targeting specific molecules or receptors on cancer cells to block cancer cell growth signals and promote immune-mediated killing.

Therapeutic Polyclonal Antibody

Therapeutic Polyclonal Antibody

Coverage of a wider range of cancer cell targets, enhancement of anti-cancer immune responses, and improved efficacy of cancer therapies.

Therapeutic Bispecific Antibody

Therapeutic Bispecific Antibody

By bridging the gap between cancer cells and immune cells, it enhances the immune cell-mediated killing of cancer cells.

Therapeutic Multispecific Antibody

Therapeutic Multispecific Antibody

Simultaneously targeting multiple cancer-associated antigens or pathways, it overcomes cancer resistance mechanisms, thereby increasing therapeutic potential.

Therapeutic Antibody Fragment

Therapeutic Antibody Fragment

As a mini-engineered version of the antibody, it offers potential advantages such as improved tissue penetration, reduced immunogenicity, and easier production.

Antibody Drug Conjugate

Antibody Drug Conjugate

Combines the targeting ability of an antibody with a cytotoxic payload linked via cleavable or non-cleavable junctions.

One-stop Therapeutic Antibody Development

Alfa Cytology, a leading CRO, offers a comprehensive range of services for streamlined antibody development, serving as a convenient one-stop solution.

Antigen Development Service

Antigen Development Service

High-quality antigens are used to stimulate the immune system to produce specific antibodies to facilitate the development of targeted immunotherapies for cancer.

Antibody Discovery Services

Antibody Discovery Services

Advanced technologies such as phage display, hybridoma technology, or single-cell sequencing are used to identify and isolate novel antibodies with high affinity and specificity against cancer-specific targets.

Antibody Optimization and Engineering Service

Antibody Optimization and Engineering Service

Modify and improve the properties of therapeutic antibodies to enhance their efficacy, stability, and safety in order to optimize the therapeutic potential of antibodies in cancer treatment.

Antibody Characterization Service

Antibody Characterization Service

Antibody characterization services provide comprehensive analysis and evaluation of an antibody's binding specificity, affinity, stability, and pharmacokinetic properties.

Workflow of Therapeutic Antibody Development

Target Identification

Identifying potential target molecules that are involved in the disease pathway through genomics and proteomics.

01

Target Validation

The identified targets are further validated to ensure their relevance and suitability as therapeutic targets.

02

Antibody Generation

Generation of specific anti-cancer antibodies using hybridoma technology, phage display, and transgenic animals.

03

Lead Antibody Selection

Functional assays and engineering techniques are applied to optimize their therapeutic potential.

04

Preclinical Studies

Efficacy, safety, pharmacokinetics, and pharmacodynamics are tested in relevant disease models.

05

Our Advantages

Largest Toolbox

Largest Toolbox

Strong Expertise

Strong Expertise

One-stop Solution

One-stop Solution

Short Turnaround

Short Turnaround

Nowadays, tremendous progress has been made in antibody-based cancer therapies. Alfa Cytology is providing a solid foundation for potential novel therapies by facilitating the development of therapeutic antibodies. Please contact us for more information.

Reference

  1. Carter, P. J., & Rajpal, A. (2022). Designing antibodies as therapeutics. Cell185(15), 2789-2805.

For research use only.